CA3159315A1 - Ahr inhibitors and uses thereof - Google Patents

Ahr inhibitors and uses thereof Download PDF

Info

Publication number
CA3159315A1
CA3159315A1 CA3159315A CA3159315A CA3159315A1 CA 3159315 A1 CA3159315 A1 CA 3159315A1 CA 3159315 A CA3159315 A CA 3159315A CA 3159315 A CA3159315 A CA 3159315A CA 3159315 A1 CA3159315 A1 CA 3159315A1
Authority
CA
Canada
Prior art keywords
cancer
compound
sdi
detected
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3159315A
Other languages
English (en)
French (fr)
Inventor
Alfredo C. Castro
James Martin Nolan Iii
Xiaoyan Michelle ZHANG
Jason SAGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImageneBio Inc
Original Assignee
Ikena Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikena Oncology Inc filed Critical Ikena Oncology Inc
Publication of CA3159315A1 publication Critical patent/CA3159315A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3159315A 2019-11-26 2020-11-25 Ahr inhibitors and uses thereof Pending CA3159315A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940514P 2019-11-26 2019-11-26
US62/940,514 2019-11-26
US202063106530P 2020-10-28 2020-10-28
US63/106,530 2020-10-28
PCT/US2020/062116 WO2021108469A1 (en) 2019-11-26 2020-11-25 Ahr inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3159315A1 true CA3159315A1 (en) 2021-06-03

Family

ID=73856333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3159315A Pending CA3159315A1 (en) 2019-11-26 2020-11-25 Ahr inhibitors and uses thereof

Country Status (11)

Country Link
US (1) US20230026232A1 (enExample)
EP (1) EP4065090A1 (enExample)
JP (1) JP2023503167A (enExample)
KR (1) KR20220125232A (enExample)
CN (1) CN115279347A (enExample)
AU (1) AU2020391451A1 (enExample)
BR (1) BR112022010143A2 (enExample)
CA (1) CA3159315A1 (enExample)
IL (1) IL293325A (enExample)
MX (1) MX2022006312A (enExample)
WO (1) WO2021108469A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
TW202421150A (zh) * 2022-09-14 2024-06-01 美商阿克思生物科學有限公司 艾魯美冷之分散體

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3774767B1 (en) * 2018-04-05 2025-10-29 Beth Israel Deaconess Medical Center, Inc. Aryl hydrocarbon receptor modulators and uses thereof
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Also Published As

Publication number Publication date
AU2020391451A1 (en) 2022-06-16
EP4065090A1 (en) 2022-10-05
WO2021108469A1 (en) 2021-06-03
IL293325A (en) 2022-07-01
KR20220125232A (ko) 2022-09-14
MX2022006312A (es) 2022-06-22
BR112022010143A2 (pt) 2022-08-09
JP2023503167A (ja) 2023-01-26
CN115279347A (zh) 2022-11-01
US20230026232A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
US20230026232A1 (en) Ahr inhibitors and uses thereof
KR102606253B1 (ko) 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
CN109069410A (zh) 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂
TW200304379A (en) Pharmaceutical composition
CN113853374B (zh) 具有增强的生物利用度的化合物形式及其制剂
US20260035258A1 (en) Novel amorphous active pharmaceutical ingredients comprising substantially amorphous mesoporous magnesium carbonate
HK1204998A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
WO2019152798A1 (en) Pharmaceutical formulations
TWI894266B (zh) 醋酸阿比特龍和尼拉帕尼之藥物配製物
JPWO2016175230A1 (ja) 経口投与用医薬組成物
EP3860606A1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
US20220064204A1 (en) Amorphous form of 5-bromopyridin-3-yl 3-deoxy-3-[4-(3,4,5-trifluorophenyl)-1h-1,2,3-triazol-1-yl]-1-thio-alpha-d-galactopyranoside
WO2015152680A1 (en) Granule comprising silodosin, and pharmaceutical composition and formulation comprising same
JP2019529502A (ja) アルツハイマー病及びパーキンソン病を処置するための組成物及び方法
JP7849382B2 (ja) シロップ剤
US20110160213A1 (en) Pharmaceutical compositions for the treatment of inflammatory and allergic disorders
EA052058B1 (ru) Лечение рака предстательной железы с помощью комбинации абиратерона ацетата и нирапариба
EA053188B1 (ru) Фармацевтические составы на основе абиратерона ацетата и нирапариба
CN119768155A (zh) 依曲地南的分散体
EA046804B1 (ru) Форма соединения, обладающая повышенной биодоступностью, и ее составы
WO2019130194A1 (en) Novel drug products of picropodophyllin

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250825

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260318

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260402

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260525

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703